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INTRODUCTION
CD99 is an ubiquitous 32 kDa transmembrane protein
encoded by the mic2 gene. It is expressed on most of human
tissues, especially on cortical thymocytes, pancreatic islet cells,
and Leydig and Sertoli cells. So far, several anti-CD99 anti-
bodies such as 12E7, O662, L129, D44, HBA71, O13, and
DN16 have been reported, and 12E7, HBA71, O13, and
DN16 were revealed to be useful for diagnosis of tumor on
routine paraffin sections (1-5). Identification of the CD99 ex-
pression in formalin-fixed, paraffin-embedded tissues is par-
ticularly useful in differentiating Ewing's sarcoma/primitive
neuroectodermal tumors (PNETs) from other types of small
round cell tumors (1-3, 6). In addition, its expression has been
reported in lymphoblastic lymphoma/leukemia (7) and some
rhabdomyosarcoma (8). Immunohistochemical detection of
the CD99 expression has been reported in a number of other
tumors, including mesenchymal chondrosarcomas (4), chloro-
mas (9), acute myelogenous leukemia (9), some of ovarian
tumors (10), and ependymomas (5) by the antigen retrieval
technology. However, the functional significance of the CD99
expression in these tumors has not yet been known.
Recently, another isoform of CD99 (CD99 type II) was re-
ported (11). CD99 type II is a truncated isoform that is pro-
duced by alternative splicing of the CD99 gene transcript and
its molecular weight is 28 kDa. In contrast to CD99 type I,
transcripts of CD99 type II were detected at lower levels in
a cell type-specific manner (11). Since there are no anti-CD99
antibodies that are able to discriminate the two isoforms of
CD99, the tissue distribution pattern of CD99 type II has
not been reported.
CD99 type II was known to be able to functionally coun-
teract with the type I. It has been reported that the engage-
ment of CD99 induces homotypic aggregation (12), up-reg-
ulation of T cell receptor and major histocompatibility com-
plex molecules (13), and apoptosis of immature thymocytes
(14). In contrast, overexpression of the CD99 type II inhibited
the homotypic aggregation of IM-9 cells by CD99 engage-
ment (11). In addition, a recent study revealed that the trans-
fection of CD99 type II variant in carcinoma cell line enhanced
the in vitro invasiveness and matrix metalloproteinase (MMP)
activity, together with inhibition of homotypic cell adhesion
(15).
In the present study, we evaluated the expression of CD99
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Immunoreactivity of CD99 in Stomach Cancer
CD99 is characteristically expressed in Ewing's sarcoma/primitive neuroectoder-
mal tumor. Recently its immunoreactivity has also been reported in other tumors.
However, the significance of CD99 isoforms expressed in these tumors has not
been elucidated. In this study, we evaluated the expression of CD99 isoforms
and its relationship with histopathologic parameters in gastric adenocarcinomas.
Paraffin sections of 46 gastric adenocarcinomas were stained with an anti-CD99
monoclonal antibody, YG32. Twelve (26.1%) cases of 46 gastric adenocarcinomas
showed immunoreactivity to YG32. The CD99 expression was also seen both in
non-neoplastic foveolar epithelial cells and infiltrating lymphocytes. In addition,
Western blot and RT-PCR analyses revealed that the type I is the predominant
isoform of CD99 in non-neoplastic and neoplastic gastric tissues. The CD99 ex-
pression was usually seen in the intestinal type adenocarcinoma, while rarely in
the diffuse type. The CD99 immunoreactivity decreased in MMP-2-overexpress-
ing adenocarcinomas (p=0.028). Our results suggest that the type I is the major
isoform of CD99 expressed in non-neoplastic gastric mucosa and gastric adeno-
carcinomas and its downregulation in gastric adenocarcinoma may be associat-
ed with cellular dedifferentiation and/or MMP-2 overexpression. 
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antigen in gastric adenocarcinoma, which is one of the most
common cancers in Korea and also compared the CD99 im-
munoreactivity with histopathologic parameters and the ex-
pression of MMPs.
MATERIALS AND METHODS
Tissue
The tissues from 46 cases of gastric adenocarcinoma were
obtained from patients who had undergone gastrectomy at
Chunchun Sacred Heart Hospital, Chunchun, Korea, between
1999 and 2001. The gross appearance of early gastric cancer
(EGC) was classified according to the criteria by the Japanese
Gastroenterological Endoscopy Society (16). Macroscopic clas-
sification of advanced gastric cancer (AGC) was carried out
according to the Borrmann's classification (17). Each tumor
was classified on the basis of the modified WHO's classifica-
tion system (18) as follows: tubular (well differentiated, mod-
erately differentiated, and poorly differentiated), mucinous, or
signet-ring-cell carcinoma. Histological type was also classi-
fied according to the Lauren's classification (19).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were cut into
5- m serial sections, attached to silane-coated slides, deparaf-
finized in xylene, and redehydrated in phosphate-buffered
saline (PBS), pH 7.4. The deparaffinized sections were boiled
for 10 min in 0.01 M citrate buffer, pH 6.0, for antigen-re-
trieval and endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide for 30 min. Immunohistochemical
staining was performed using the LSAB kit (DAKO, Carpin-
teria, CA, U.S.A.). The deparaffinized sections were preincu-
bated with normal goat serum to prevent nonspecific binding,
and then incubated overnight at 4℃ with an optimal dilu-
tion of the primary antibodies. The sections were rinsed with
PBS and incubated with biotinylated anti-mouse immunoglob-
ulin for 1 hr at room temperature and then with streptavidin-
horseradish peroxidase conjugate. The enzyme reaction was
developed with 0.03% 3′ 3-diaminobenzidine tetrahydrochlo-
ride containing 0.006% hydrogen peroxide. As a negative
control, the primary antibodies were replaced by an irrelevant
isotype-matched antibody. YG32 (anti-CD99) antibody was
purchased from DiNonA (Seoul, Korea), and A-Gel VC2
(anti-MMP-2), SL-1 IID4 (anti-MMP-3), and IIA5 (anti-
MMP-9) antibodies were purchased from Pharmingen (San
Diego, CA, U.S.A.).
Western blotting
Frozen tissues were lysed with 1% Triton X-100 in 50 mM
Tris-HCl, pH 7.4, 50 mM EDTA, and 1 mM PMSF. The ly-
sates were mixed gently by slowly inverting the tube, incu-
bated at 4℃ for 30 min and centrifuged at 13,000 g for 15
min for removal of nuclei. The supernatant was used for SDS-
PAGE under the reduced conditions. The acrylamide concen-
tration of the separation gels was 12.5% and appropriate mo-
lecular weight markers were used. The electrophoretic transfer
of proteins to nitrocellulose was done at 30 V for 16 hr. After
protein transfer, the nonspecific binding sites of the nitrocel-
lulose were blocked by a solution of 5% skimmed milk. The
antigens were detected by incubating the paper with primary
antibodies. Horseradish peroxidase-conjugated antibody (DA-
KO) was used as a secondary antibody, followed by enhanced
chemiluminescence assay (ECL, Pharmacia, Uppsala, Sweden)
for visualization. YG32 antibody was used to detect both iso-
forms of CD99 and anti-human  - actin antibody (ACTN05;
Lab Vision, Fremont, CA, U.S.A.) was used to normalize the
amount of protein loaded.
Competitive RT-PCR
Total RNA was isolated from the frozen tissues using an
RNA extraction kit (Bioneer, Daejon, Korea) and cDNA was
first prepared by reverse transcription of 20  g RNA in a
50 L reaction volume containing PCR buffer, 1 mM DTT,
200  M dNTPs, 200 pmol oligo-dT18. The competitor for
competitive RT-PCR was prepared using a competitive DNA
construction kit (Takara, Shiga, Japan). Equal volumes of
cDNA and DNA competitor were amplified in a PCR mas-
ter mix composed of Tris-HCl, pH 9.0, 2.5 U Taq DNA
polymerase, 250  U dNTP, 40 mM KCl, and 1.5 mM MgCl2
(Bioneer, Daejon, Korea). Primers were as follows; human
CD99 type I & type II sense, 5′ -GGTTTCGATTTATCTG
ATGCC-3′ , type I antisense, 5′ -CTATTTCTCTAAAAGAG
TACG-3′ , type II antisense, 5′ - CCCTAGGTCTTCAGCC
AT-3′ ; human  -actin sense, 5′ -CAAGAGATGGCCACGG
CTGCT-3′ , antisense, 5′ -TCCTTCTGCATCCTGTCGGC
A-3′ . The CD99 type I and type II primers were predicted
to amplify 485 and 420 bp DNA fragments, respectively,
while  -actin primers generated a 275 bp-product. Samples
were heated to 94℃ for 30 sec, followed by either 55℃ for
1 min (for the CD99 primers) or 68℃ for 1 min (for the
actin primers) and then 72℃ for 1 min for 35 cycles. The
PCR products were resolved by 2% agarose gel electrophore-
sis and stained with ethidium bromide.
RESULTS
Immunoreactivity of CD99 in Non-neoplastic and Neo-
plastic Gastric Tissues
Of the 46 patients with gastric carcinomas, 27 were male
and 19 were female. The median age was 61 yr (rage, 37 to
79). Histologically, there were 23 AGCs and 23 EGCs. TheCD99 in Stomach Cancer Cells 485
histopathologic features of the cases are summarized in Table 1.
To detect the CD99 expression in non-neoplastic and neo-
plastic tissues, formalin-fixed, paraffin-embedded tissue sec-
tions were stained with an anti-CD99 antibody, YG32. Non-
neoplastic foveolar epithelial cells showed a weak immunore-
activity to CD99 (Fig. 1A). The CD99 immunoreactivity was
characteristically membranous. Strong expression of CD99
was also identified in infiltrating lymphocytes as previously
reported (20). In contrast, the CD99 protein was stained only
in 7 of 23 AGCs (30.4%) and 5 of 23 EGCs (21.7%). The
immunoreactivity in carcinoma cells was usually stronger
than that in non-neoplastic epithelium. Characteristically,
CD99 immunoreactivity was detected only in the intestinal-
and mixed-type adenocarcinomas except for one case (Fig. 1B,
Table 2). In the three CD99-poisitive adenocarcinomas of
mixed types, the CD99 immunoreactivity was mostly detect-
ed in the glandular components, while CD99 was rarely ex-
pressed in the diffuse component (Fig. 1C and 1D). In addi-
tion, highly anaplastic tumor cells were not stained by anti-
CD99 antibody, either (Fig. 1E). Among adenocarcinomas of
the diffuse type, CD99-immunoreactivity was found in only
Histologic type (WHO classification)
Tubular
Well differentiated
Moderately differentiated
Poorly differentiated
Mucinous
Signet ring cell
Histologic type (Lauren's classification)
Intestinal
Mixed
Diffuse
Depth of invasion
Mucosa
Submucosa
Proper muscle
Subserosa
Serosa and omentum
Lymph node metastasis
Present
Absent
9
13
1
7
6
10
4
1
18
17
6
6
9
5
3
15
8
13
10
0
23
AGC (n=23) EGC (n=23)
Table 1. Clinicopathological features of 46 gastric adenocarci-
nomas
Fig. 1. Immunohistochemistry for CD99 in gastric adenocarcinoma. CD99 is expressed in the non-neoplastic gastric mucosa (A).
Among the carcinomas, the expression of CD99 is identified predominantly in the intestinal (B) and mixed types (C). In the cases of
CD99-positive carcinomas of the mixed type, the CD99 expression is positive in the glandular component (C) but negative in the dif-
fuse component (D). In addition, highly atypical cells are not stained by an anti-CD99 antibody (E). Among adenocarcinomas of the
diffuse type, only one case shows immunoreactivity for CD99 (F). (×200).
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one case (Fig. 1F). 
Isotypes of CD99 Expressed in Gastric Cancer
So far there has been no anti-CD99 antibody that can dis-
criminate CD99 type II from CD99 type I. The two isoforms
of CD99 could thus be identified only by Western blotting
or RT-PCR. To determine which isoform of CD99 antigens
is expressed in gastric tissues, cancerous and noncancerous
tissues in the 25 gastric adenocarcinomas were analyzed by
Western blot analysis. Use of human thymus as a positive
control confirmed that the YG32 antibody was reactive with
both long (32 kDa) and short forms (28 kDa) of CD99 (Fig.
2A). Cell extract from tumor and normal tissues produced a
band at 32 kDa, which indicated the CD99 type I, whereas
the short form of CD99 was not detected in any case. How-
ever, the CD99 type I band was detected both in CD99-posi-
tive and CD99-negative tumor tissues and the band intensity
was not correlated with immunoreactivity in paraffin-embed-
ded tissue. This may be due to the CD99 antigen expressed
in reactive lymphocytes (Fig. 2A).
We also performed competitive RT-PCR by using primers
specific for the CD99 type I and type II transcripts to detect
the expression of CD99 isoforms even at a very low level. In
agreement with results from Western blot analysis, the tran-
scripts of CD99 type I were detected in all cases, and the
expression level of CD99 type I mRNA was not correlated
with immunoreactivity in paraffin-embedded tissue (data
not shown). In addition, the transcripts of CD99 type II were
detected in both CD99-positive and CD99-negative tumor
tissues (Fig. 2B), indicating the low level expression of CD99
type II in stomach tissues. However, there was no difference
in the transcript level of CD99 type II between CD99-posi-
tive and CD99-negative tumor tissues. These results suggest
that the immunoreactivity of CD99 in gastric carcinoma cells
may not be due to the overexpression of CD99 type II.
Lauren's classification
Intestinal
Mixed
Diffuse
46
22
6
18
34 (73.9%)
14 (63.6%)
3 (50.0%)
17 (94.4%)
12 (26.1%)
8 (36.4%)
3 (50.0%)
1 (5.6%)
n
Table 2. Immunoreactivity of CD99 in gastric adenocarcinomas
CD99
- +
CD99 + 8 6 2* 4 4 3 5
CD99 - 17 4 13* 10 7 10 7
Total 25 10 15 14 11 13 12
n
Table 3. MMP Immunoreactivity of tumor cells in gastric adeno-
carcinomas
MMP-2
- +
MMP-3
- +
MMP-9
- +
*p=0.028; Fisher's exact test.
Fig. 3. Immunohistochemistry for MMP-2 (A), MMP-3 (B), and MMP-
9( C) in advanced gastric adenocarcinoma. MMPs are expressed
in the cytoplasm of tumor cells (×200).
Fig. 2. Identification of the CD99 isoforms expressed in non-neo-
plastic and carcinoma tissues. (A) Western blot analysis. Total
lysates were prepared from non-neoplastic (N) and tumor (T) tis-
sues and the CD99 expression was detected using an anti-CD99
antibody, YG32. Type I CD99 (32 kDa) is detected in both CD99-
negative (left four lanes) and CD99-positive (right four lanes) cases,
while the type II isoform (28 kDa) is not detected in any case. The
amount of protein in samples was normalized by Western blot-
ting of the human  -actin protein (42 kDa). (B) Competitive RT-
PCR analysis of CD99 type II mRNA expression in CD99-nega-
tive (left four lanes) and CD99-positive (right four lanes) tumor tis-
sues using the specific primer pairs predicted to amplify the type
II isoform of CD99 mRNA. The amount of mRNA in samples was
normalized by competitive RT-PCR of human  -actin.
A
B
C
A
B
42 kDa
CD99-
N     T     N     T
CD99+
Thymocyte
N     T     N     T
CD99- CD99+
Competitor
-Actin
32 kDa
28 kDa
Competitor
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Expression of MMP-2, MMP-3, and MMP-9 in Gastric
Cancer
Although various functions of CD99 in lymphoid cells have
been reported, the function of CD99 in tumorigenesis has
not been elucidated. Only a recent research using carcinoma
cell lines suggested that the overexpression of CD99 type II
enhances the in vitro invasiveness and MMP activity (15). In
addition, it has been reported that the expression of MMP-2
and MMP-9 was increased in gastric cancers (21-24). There-
fore, in order to analyze the possible relationship between
CD99 immunoreactivity and the expression of MMPs in gas-
tric adenocarcinomas, immunohistochemical analysis was
performed. MMP-2 was not expressed in any of the normal
gastric epithelium studied. In contrast, 15 of 25 cases (60.0%)
of gastric carcinoma showed immunoreactivity for MMP-2
in the carcinoma cells (Fig. 3A, Table 3). In 8 CD99-positive
cases, MMP-2 immunoreactivity was detected only in 2 cases
(25.0%), while 13 (76.5%) of 17 CD99-negative cases showed
MMP-2 immunoreactivity. These results showed an inverse
relationship between MMP-2 overexpression and CD99 im-
munoreactivity (p=0.028). MMP-3 and MMP-9 immuno-
reactivities were also detected in tumor cells of gastric adeno-
carcinoma (in 11, 12 cases, respectively; Fig. 3, Table 3).
However, there was no relation between the MMP-3 or MMP-
9 expression and CD99 immunoreactivity.
DISCUSSION
In soft tissue tumors, the CD99 expression has long been
used as a diagnostic marker for Ewing's sarcoma/PNET (1-
3, 6), and recently, many other tumors have been addeded
to the list of tumors with CD99 immunoreactivity (4, 5, 7-
10). Nevertheless, the isoforms of CD99 expressed in these
tumors have not yet been determined. Thus, we examined
the expression of each type of CD99 in non-neoplastic and
neoplastic gastric tissues and analyzed the relationship be-
tween CD99 expression and histopathologic parameters and
MMP immunoreactivity.
Advances in antigen retrieval technology as well as the de-
velopment of new antibodies against the CD99 antigen have
contributed to the detection of CD99 in more tumor cases.
Thus, we performed immunohistochemical analysis in sto-
mach cancer tissues after microwave treatment in citrate buf-
fer, through which we could detect the expression of CD99
antigen in normal foveolar epithelial cells and infiltrating
lymphocytes. The CD99 immunoreactivity was characteris-
tically membranous in these cells. In contrast, only 23%
cases of gastric adenocarcinoma showed CD99 immunoreac-
tivity. The immunoreactivity of CD99 was not correlated
with age, depth of invasion, or lymph node metastasis. How-
ever, CD99 immunoreactivity was mostly detected in ade-
nocarcinomas of the intestinal type or glandular component
of the mixed type. In addition, highly anaplastic tumor cells
did not express the CD99 antigen. Thus, these results imply
that CD99 is expressed both in normal gastric epithelum and
adenocarcinoma cells which show glandular differentiation
(intestinal type), while CD99 expression is decreased in ade-
nocarciconomas of diffue type, in which tumor cells are less
differentiated. To identify the isoform of CD99 expressed in
non-neoplastic and neoplastic gastric tissues, Western blot-
ting was performed and only the type I isoform of 32 kDa
in molecular weight was detected. Although the transcripts
of CD99 type II were detected in non-neoplastic and neoplas-
tic tissues by RT-PCR, there was no difference in the expres-
sion level of mRNA of CD99 type II between CD99-posi-
tive and CD99-negative cases. Thus, all these features suggest
that the CD99 type I is the predominant isoform that is ex-
pressed both in non-neoplastic and neoplastic gastric tissues
and the loss of CD99 immunoreactivity in gastric adenocar-
cinomas may be associated with dedifferentiaton of tumor
cells.
Previous studies showed that the balance between the two
CD99 isoforms affect the cell adhesion (11, 15). In addition,
overexpression of CD99 type II enhanced the MMP activity
in a carcinoma cell line (15). These results raised the possi-
bility that the downregulation of CD99 type I expression or
upregulation of CD99 type II expression may enhance the
invasiveness of tumor cells by affecting cell adhesion or MMP
activity. Thus, much attention has focused on the difference
in the level of MMP expression between CD99-positive and
CD99-negative cases.
MMPs are zinc-dependent enzymes that are involved in
the degradation of the extracellular matrix. On the basis of
their substrate specificities and structural homology, MMPs
can be classified into subgroups of collagenases (MMP-1,
MMP-8, and MMP-13), gelatinases (MMP-2 and MMP-9),
stromelysins (MMP-3, MMP-10, MMP-12, and MMP-7),
membrane-type MMPs (MT-MMPs) and other MMPs (25-
26). MMPs have been considered to play significant roles in
tumor invasion and metastasis (25). Especially, MMP-2 (gela-
tinase A, 72-kDa type IV collagenase) is well known as a de-
composing enzyme of type IV collagen, laminin, and fibro-
nectin, all of which are components of the basement mem-
brane, and its relationship to the depth of invasion, metasta-
sis in regional lymph nodes, and prognosis of gastric cancer
has been reported (22, 27). In our study, MMP-2 was detected
in 15 (60.0%) out of 25 gastric adenocarcinomas. Among
the 8 CD99-positive cases, only two (25.0%) were MMP-2-
positive, while MMP-2 immunoreactivity was detected in 13
(76.5%) out of 17 CD99-negative cases. These results sug-
gest that MMP-2 overexpression in gastric adenocarcinoma
may be associated with the downregulation of CD99 type I
and thus support the in vitro data that the balance between
the two CD99 isoforms contributes to the MMP activity.
In addition to MMP-2, MMP-3 and MMP-9 are involved
in carcinogenesis and tumor invasion. MMP-9 (gelatinase B,488 K.C. Jung, W.S. Park, Y.M. Bae, et al.
92-kDa type IV collagenase) have a gelatin-binding domain
and its structure is similar to that of MMP-2 (25), wherease
MMP-3 (stromelysin-1) is a member of stromelysins and can
degrade collagens III, IV, V, IX, X, and XI, laminins, elastin,
entactin, fibronectin, fibrin, fibrillins, fibulin, link protein,
osteonectin, tenascin, vitronectin, and ECM proteoglycans
(28). The expression of MMP-9 is associated with lymph node
metastasis in gastric cancer (24), and the immunoreactivity
for MMP-3 has also been reported in some cases of gastric
cancers (21). In our study, 11 (44.0%) of 25 gastric carcinoma
cases showed immunoreactivity for MMP-3 in tumor cells
and MMP-9 was overexpressed in 12 cases (48.0%). How-
ever, MMP-3 or MMP-9 immunoreactivity was not corre-
lated with CD99 immunoreactivity.
CD99 is expressed on most of human tissues and the sig-
nificant role of CD99 in tumorigenesis was only documented
in Hodgkin's disease, in which the loss of CD99 has been
shown to play a critical role in the formation of Hodgkin's
and Reed-Sternberg cells (29-31). The results from our study
also suggest that the downregulation of CD99 type I could
be associated with dedifferentiation of tumor cells in gastric
adenocarcinomas. Thus, it seems that the downregulation of
CD99 expression rather than its overexpression may play a
functionally significant role in tumorigenesis or tumor pro-
gression.
In conclusion, our findings suggest that the downregula-
tion of CD99 type I expression may be associated with de-
differentiation of tumor cells and overexpression of MMP-2
in gastric adenocarcinomas.
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